endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.15829/2713-0177-2023-3-15endofocus-47Research ArticleСтатьиВзаимосвязь эндокринной и гастроэнтерологической патологии: пищевые волокна как механизм управленияThe relationship of endocrine and gastroenterological pathology: dietary fiber as a mechanism of managementhttps://orcid.org/0000-0002-6826-5924ТепловаА. С.TeplovaA. S.

Ассистент кафедры эндокринологии лечебного факультета

117997, Россия, Москва, ул. Островитянова, д. 1 

Anna S. Teplova – Assistant, Department of Endocrinology, Faculty of Medicine 

117997, Moscow, st. Ostrovityanova, 1

anna_kochina_@mail.ruhttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Y.

Д.м.н., профессор, заведующий кафедрой эндокринологии лечебного факультета

Scopus ID: 7003771623 

117997, Россия, Москва, ул. Островитянова, д. 1 

Tatyana Y. Demidova – Can. Sci. (Med.), Assistant, Department of Endocrinology, Faculty of Medicine

117997, Moscow, st. Ostrovityanova, 1

t.y.demidova@gmail.comhttps://orcid.org/0000-0002-3656-0312ЛобановаК. Г.LobanovaK. G.

 Ассистент кафедры эндокринологии лечебного факультета 

117997, Россия, Москва, ул. Островитянова, д. 1 

Kristina G. Lobanova –Doctor of Medical Sciences, Professor, Head of the Department of Endocrinology, Faculty of Medicine 

117997, Moscow, st. Ostrovityanova, 1

miss.sapog@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской ФедерацииFederal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation20231812202343Гастроэндокринология4855Copyright © Теплова А.С., Демидова Т.Ю., Лобанова К.Г., 20242024Теплова А.С., Демидова Т.Ю., Лобанова К.Г.Teplova A.S., Demidova T.Y., Lobanova K.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/47

Гастроэнтерологические проявления эндокринных заболеваний являются дополнительным фактором, снижающим качество жизни пациентов. В ряде случаев гастроэнтерологические симптомы являются причиной обращения пациента за медицинской помощью и, соответственно, выявления эндокринного заболевания. Патогенетические аспекты развития нарушений со стороны желудочно-кишечного тракта многообразны, в связи с чем, к сожалению, не всегда удается устранить гастроэнтерологические симптомы с помощью компенсации основного заболевания. Сочетание патологии желудочно-кишечного тракта и эндокринной системы может взаимно отягощать течение обоих заболеваний. Нередки случаи, когда патология желудочно-кишечного тракта может быть первопричиной некоторых метаболических заболеваний, в частности, синдром мальабсорбции. В настоящее время широко изучаются возможности коррекции гастроэнтерологической патологии с целью достижения компенсации имеющейся у пациента эндокринной патологии, а также повышения качества жизни пациентов. Основными направлениями являются мероприятия, направленные на восстановление пассажа пищевого содержимого, поддержание целостности кишечной стенки, устранение воспалительного фактора, а также восстановление кишечной микробиоты (КМ) и модуляцию ее метаболизма. Последний способ коррекции нарушений на сегодняшний день представляется наиболее перспективным в связи с постоянно растущим количеством научных публикаций, а также широким спектром безопасных и эффективных возможностей воздействия на КМ. Помимо диетических рекомендаций все большую актуальность приобретает вопрос назначения пациентам пищевых волокон (ПВ) как пищевого субстрата для КМ и механизма управления количеством и соотношением микроорганизмов.

Gastroenterological manifestations of endocrine diseases are an additional factor that reduces the quality of life of patients. In some cases, gastroenterological symptoms are the reason for the patient’s coming to the doctor and the detection of endocrine disease. The pathogenetic aspects of the development of disorders of the gastrointestinal tract are diverse, and therefore, unfortunately, it is not always possible to eliminate gastroenterological symptoms by only compensating the underlying disease. The combination of pathology of the gastrointestinal tract and the endocrine system can mutually aggravate the course of each other. There are also cases when gastroenterological pathology can be the root cause of some metabolic diseases, in particular, malabsorption. Currently, the possibilities of correction of gastroenterological pathology are widely studied in order to achieve compensation for the patient’s endocrine pathology, as well as to improve the quality of life of patients. The main directions are measures aimed at restoring the passage of food contents, maintaining the integrity of the intestinal wall, eliminating the inflammatory factor, as well as restoring the gu microbiota (GM) and modulating its metabolism. The latter method of correcting violations seems to be the most promising today due to the constantly growing number of scientific publications, as well as a wide range of safe and effective ways to influence GM. In addition to dietary recommendations, the issue of prescribing dietary fiber (DF) to patients as a food substrate for GM and a mechanism for controlling the number and ratio of microorganisms is becoming increasingly relevant.

эндокринные заболеванияжелудочно-кишечный трактщитовидная железаостеопорозкишечная микробиотапищевые волокнаendocrine diseasesgastrointestinal tractthyroid glandosteoporosisgut microbiotadietary fiberReferencesSchwartz S.S., Epstein S., Corkey B.E., Grant S.F., Gavin J.R. 3rd, Aguilar R.B. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care. 2016;39:179–186.Schwartz S.S., Epstein S., Corkey B.E., Grant S.F., Gavin J.R. 3rd, Aguilar R.B. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. Diabetes Care. 2016;39:179–186.Маев И.В., Андреев Д.Н., Самсонов А.А., Черёмушкина А.С. Язвенная болезнь: современное состояние проблемы. Медицинский совет. 2022;16(6):100–108. https://doi.org/10.21518/2079-701X-2022-16-6-100-108.Маев И.В., Андреев Д.Н., Самсонов А.А., Черёмушкина А.С. Язвенная болезнь: современное состояние проблемы. Медицинский совет. 2022;16(6):100–108. https://doi.org/10.21518/2079-701X-2022-16-6-100-108.Brechmann T., Sperlbaum A., Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study. World J. Gastroenterol. 2017;23:842–852. doi: 10.3748/wjg.v23.i5.842.Brechmann T., Sperlbaum A., Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study. World J. Gastroenterol. 2017;23:842–852. doi: 10.3748/wjg.v23.i5.842.Konrad P., Chojnacki J., Kaczka A., Pawłowicz M., Rudnicki C., Chojnacki C. Thyroid dysfunction in patients with small intestinal bacterial overgrowth. Pol. Merkur. Lek. 2018;44:15–18.Konrad P., Chojnacki J., Kaczka A., Pawłowicz M., Rudnicki C., Chojnacki C. Thyroid dysfunction in patients with small intestinal bacterial overgrowth. Pol. Merkur. Lek. 2018;44:15–18.Boutzios G., Koukoulioti E., Goules A.V., Kalliakmanis I., Giovannopoulos I., Vlachoyiannopoulos P., Tzioufas A.G. Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. Front. Endocrinol. 2022;13:860880. doi: 10.3389/fendo.2022.860880.Boutzios G., Koukoulioti E., Goules A.V., Kalliakmanis I., Giovannopoulos I., Vlachoyiannopoulos P., Tzioufas A.G. Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. Front. Endocrinol. 2022;13:860880. doi: 10.3389/fendo.2022.860880.Marshall LL. Gastrointestinal bleeding and possible hypothyroidism. Consult Pharm. 2012 Mar;27(3):180-8. doi: 10.4140/TCP.n.2012.180. PMID: 22421518.Marshall LL. Gastrointestinal bleeding and possible hypothyroidism. Consult Pharm. 2012 Mar;27(3):180-8. doi: 10.4140/TCP.n.2012.180. PMID: 22421518.Ruscio M, Guard G, Piedrahita G, D’Adamo CR. The Relationship between Gastrointestinal Health, Micronutrient Concentrations, and Autoimmunity: A Focus on the Thyroid. Nutrients. 2022 Aug 30;14(17):3572. doi: 10.3390/nu14173572.Ruscio M, Guard G, Piedrahita G, D’Adamo CR. The Relationship between Gastrointestinal Health, Micronutrient Concentrations, and Autoimmunity: A Focus on the Thyroid. Nutrients. 2022 Aug 30;14(17):3572. doi: 10.3390/nu14173572.Livadas S., Bothou C., Androulakis I., Boniakos A., Angelopoulos N., Duntas L. Levothyroxine replacement therapy and overuse: A timely diagnostic approach. Thyroid. 2018;28:1580–1586. doi: 10.1089/thy.2018.0014.Livadas S., Bothou C., Androulakis I., Boniakos A., Angelopoulos N., Duntas L. Levothyroxine replacement therapy and overuse: A timely diagnostic approach. Thyroid. 2018;28:1580–1586. doi: 10.1089/thy.2018.0014.Abu-Helalah M., Alshraideh H.A., Al-Sarayreh S.A., Al-Hader A. Transient high thyroid stimulating hormone and hypothyroidism incidence during follow up of subclinical hypothyroidism. Endocr. Regul. 2021;55:204–214. doi: 10.2478/enr-2021-0022.Abu-Helalah M., Alshraideh H.A., Al-Sarayreh S.A., Al-Hader A. Transient high thyroid stimulating hormone and hypothyroidism incidence during follow up of subclinical hypothyroidism. Endocr. Regul. 2021;55:204–214. doi: 10.2478/enr-2021-0022.Bertalot G., Montresor G., Tampieri M., Spasiano A., Pedroni M., Milanesi B., Negrini R. Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin. Endocrinol. 2004;61:650–652. doi: 10.1111/j.1365-2265.2004.02137.x.Bertalot G., Montresor G., Tampieri M., Spasiano A., Pedroni M., Milanesi B., Negrini R. Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin. Endocrinol. 2004;61:650–652. doi: 10.1111/j.1365-2265.2004.02137.x.Bugdaci M.S., Zuhur S.S., Sokmen M., Toksoy B., Bayraktar B., Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16:124–130. doi: 10.1111/j.1523-5378.2011.00830.x.Bugdaci M.S., Zuhur S.S., Sokmen M., Toksoy B., Bayraktar B., Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16:124–130. doi: 10.1111/j.1523-5378.2011.00830.x.Centanni M., Gargano L., Canettieri G., Viceconti N., Franchi A., Fave G.D., Annibale B. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. New Engl. J. Med. 2006;354:1787–1795. doi: 10.1056/NEJMoa043903.Centanni M., Gargano L., Canettieri G., Viceconti N., Franchi A., Fave G.D., Annibale B. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. New Engl. J. Med. 2006;354:1787–1795. doi: 10.1056/NEJMoa043903.de Oliveira G.L.V., Leite A.Z., Higuchi B.S., Gonzaga M.I., Mariano V.S. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017;152:1–12. doi: 10.1111/imm.12765.de Oliveira G.L.V., Leite A.Z., Higuchi B.S., Gonzaga M.I., Mariano V.S. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017;152:1–12. doi: 10.1111/imm.12765.Köhling H.L., Plummer S.F., Marchesi J.R., Davidge K.S., Ludgate M. The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. Clin. Immunol. 2017;183:63–74. doi: 10.1016/j.clim.2017.07.001.Köhling H.L., Plummer S.F., Marchesi J.R., Davidge K.S., Ludgate M. The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. Clin. Immunol. 2017;183:63–74. doi: 10.1016/j.clim.2017.07.001.Fröhlich E., Wahl R. Microbiota and thyroid interaction in health and disease. Trends Endocrinol. Metab. 2019;30:479–490. doi: 10.1016/j.tem.2019.05.008.Fröhlich E., Wahl R. Microbiota and thyroid interaction in health and disease. Trends Endocrinol. Metab. 2019;30:479–490. doi: 10.1016/j.tem.2019.05.008.Heubi JE, Partin JC, Schubert WK. Hypocalcemia and steatorrhea--clues to etiology. Dig Dis Sci. 1983;28:124–128.Heubi JE, Partin JC, Schubert WK. Hypocalcemia and steatorrhea--clues to etiology. Dig Dis Sci. 1983;28:124–128.Peracchi M, Bardella MT, Conte D. Late-onset idiopathic hypoparathyroidism as a cause of diarrhoea. Eur J Gastroenterol Hepatol. 1998;10:163–165.Peracchi M, Bardella MT, Conte D. Late-onset idiopathic hypoparathyroidism as a cause of diarrhoea. Eur J Gastroenterol Hepatol. 1998;10:163–165.Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 1995;222:402–412.Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 1995;222:402–412.Gardner EC, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. South Med J. 1981;74:197–199.Gardner EC, Hersh T. Primary hyperparathyroidism and the gastrointestinal tract. South Med J. 1981;74:197–199.Sharma S, Longo WE, Baniadam B, Vernava AM. Colorectal manifestations of endocrine disease. Dis Colon Rectum. 1995;38:318–323.Sharma S, Longo WE, Baniadam B, Vernava AM. Colorectal manifestations of endocrine disease. Dis Colon Rectum. 1995;38:318–323.Ward JB, Petersen OH, Jenkins SA, Sutton R. Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Lancet. 1995;346:1016–1019.Ward JB, Petersen OH, Jenkins SA, Sutton R. Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Lancet. 1995;346:1016–1019.Mithöfer K, Fernández-del Castillo C, Frick TW, Lewandrowski KB, Rattner DW, Warshaw AL. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology. 1995;109:239–246.Mithöfer K, Fernández-del Castillo C, Frick TW, Lewandrowski KB, Rattner DW, Warshaw AL. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology. 1995;109:239–246.Frame B, Haubrich WS. Peptic ulcer and hyperparathyroidism: a survey of 300 ulcer patients. Arch Intern Med. 1960;105:536–541.Frame B, Haubrich WS. Peptic ulcer and hyperparathyroidism: a survey of 300 ulcer patients. Arch Intern Med. 1960;105:536–541.Ellison EH, Abrams JS, Smith DJ. A postmortem analysis of 812 gastroduodenal ulcers found in 20,000 consecutive autopsies, with emphasis on associated endocrine disease. Am J Surg. 1959;97:17–30.Ellison EH, Abrams JS, Smith DJ. A postmortem analysis of 812 gastroduodenal ulcers found in 20,000 consecutive autopsies, with emphasis on associated endocrine disease. Am J Surg. 1959;97:17–30.Ostrow JD, Blanshard G, Gray SJ. Peptic ulcer in primary hyperparathyroidism. Am J Med. 1960;29:769–779 Barreras RF, Donaldson RM. Role of calcium in gastric hypersecretion, parathyroid adenoma and peptic ulcer. N Engl J Med. 1967;276:1122–1124.Ostrow JD, Blanshard G, Gray SJ. Peptic ulcer in primary hyperparathyroidism. Am J Med. 1960;29:769–779 Barreras RF, Donaldson RM. Role of calcium in gastric hypersecretion, parathyroid adenoma and peptic ulcer. N Engl J Med. 1967;276:1122–1124.Castle C, Tietjens J. Perforated gastric ulcer as the initial manifestation of hyperparathyroidism. BMJ Case Rep. 2021 Apr 13;14(4):e240570. doi: 10.1136/bcr-2020-240570.Castle C, Tietjens J. Perforated gastric ulcer as the initial manifestation of hyperparathyroidism. BMJ Case Rep. 2021 Apr 13;14(4):e240570. doi: 10.1136/bcr-2020-240570.Stenson WF: Increased prevalance of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005, 165, 393–399.Stenson WF: Increased prevalance of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005, 165, 393–399.Mulder ChJ: Celiac Disease Presenting as Severe Osteopenia. Hawaii Med J 2011, 70, 242–244.Mulder ChJ: Celiac Disease Presenting as Severe Osteopenia. Hawaii Med J 2011, 70, 242–244.Walker MD, Williams J, Lewis SK, Bai JC, Lebwohl B, Green PHR. Measurement of Forearm Bone Density by Dual Energy X-Ray Absorptiometry Increases the Prevalence of Osteoporosis in Men With Celiac Disease. Clin Gastroenterol Hepatol. 2020;18(1):99–106.Walker MD, Williams J, Lewis SK, Bai JC, Lebwohl B, Green PHR. Measurement of Forearm Bone Density by Dual Energy X-Ray Absorptiometry Increases the Prevalence of Osteoporosis in Men With Celiac Disease. Clin Gastroenterol Hepatol. 2020;18(1):99–106.Krela-Kaźmierczak I, Szymczak A, Łykowska-Szuber L, Eder P, Linke K. Osteoporosis in Gastrointestinal Diseases. Adv Clin Exp Med. 2016 Jan-Feb;25(1):185-90. doi: 10.17219/acem/33746.Krela-Kaźmierczak I, Szymczak A, Łykowska-Szuber L, Eder P, Linke K. Osteoporosis in Gastrointestinal Diseases. Adv Clin Exp Med. 2016 Jan-Feb;25(1):185-90. doi: 10.17219/acem/33746.Kondapalli AV, Walker MD. Celiac disease and bone. Arch Endocrinol Metab. 2022 Nov 11;66(5):756-764. doi: 10.20945/2359-3997000000561.Kondapalli AV, Walker MD. Celiac disease and bone. Arch Endocrinol Metab. 2022 Nov 11;66(5):756-764. doi: 10.20945/2359-3997000000561.Diez-Sampedro A., Olenick M., Maltseva T., Flowes M. A Gluten-Free Diet, Not an Appropriate Choice Without a Medical Diagnosis. J. Nutr. Metab. 2019;2019 doi: 10.1155/2019/2438934.Diez-Sampedro A., Olenick M., Maltseva T., Flowes M. A Gluten-Free Diet, Not an Appropriate Choice Without a Medical Diagnosis. J. Nutr. Metab. 2019;2019 doi: 10.1155/2019/2438934.Melini V., Melini F. Gluten-free diet: Gaps and needs for a healthier diet. Nutrients. 2019;11:170. doi: 10.3390/nu11010170.Melini V., Melini F. Gluten-free diet: Gaps and needs for a healthier diet. Nutrients. 2019;11:170. doi: 10.3390/nu11010170.Kałużna M, Kompf P, Wachowiak-Ochmańska K, Moczko J, Królczyk A, Janicki A, Szapel K, Grzymisławski M, Ruchała M, Ziemnicka K. Are patients with polycystic ovary syndrome more prone to irritable bowel syndrome? Endocr Connect. 2022 Apr 26;11(4):e210309. doi: 10.1530/EC-21-0309.Kałużna M, Kompf P, Wachowiak-Ochmańska K, Moczko J, Królczyk A, Janicki A, Szapel K, Grzymisławski M, Ruchała M, Ziemnicka K. Are patients with polycystic ovary syndrome more prone to irritable bowel syndrome? Endocr Connect. 2022 Apr 26;11(4):e210309. doi: 10.1530/EC-21-0309.Torres P J, Siakowska M, Banaszewska B. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism [J] doi:10.1210/jc.2017-02153. J Clin Endocrinol Metab. 2018;103:1502–1511.Torres P J, Siakowska M, Banaszewska B. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism [J] doi:10.1210/jc.2017-02153. J Clin Endocrinol Metab. 2018;103:1502–1511.Insenser M, Murri M, Del Campo R. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. doi:10.1210/jc.2017-02799. J Clin Endocrinol Metab. 2018;103:2552–2562.Insenser M, Murri M, Del Campo R. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. doi:10.1210/jc.2017-02799. J Clin Endocrinol Metab. 2018;103:2552–2562.Пырьева Екатерина Анатольевна, & Сафронова Адиля Ильгизовна (2019). Роль и место пищевых волокон в структуре питания населения. Вопросы питания, 88 (6), 5-11. doi: 10.24411/0042-8833-2019-10059.Пырьева Екатерина Анатольевна, & Сафронова Адиля Ильгизовна (2019). Роль и место пищевых волокон в структуре питания населения. Вопросы питания, 88 (6), 5-11. doi: 10.24411/0042-8833-2019-10059.Ashaolu TJ. Immune boosting functional foods and their mechanisms: A critical evaluation of probiotics and prebiotics. Biomed Pharmacother. 2020 Oct;130:110625. doi: 10.1016/j.biopha.2020.110625.Ashaolu TJ. Immune boosting functional foods and their mechanisms: A critical evaluation of probiotics and prebiotics. Biomed Pharmacother. 2020 Oct;130:110625. doi: 10.1016/j.biopha.2020.110625.Talebi S., Karimifar M., Heidari Z., Mohammadi H., Askari G. The effects of synbiotic supplementation on thyroid function and inflammation in hypothyroid patients: A randomized, double-blind, placebo-controlled trial. Complementary Ther. Med. 2020;48:102234. doi: 10.1016/j.ctim.2019.102234.Talebi S., Karimifar M., Heidari Z., Mohammadi H., Askari G. The effects of synbiotic supplementation on thyroid function and inflammation in hypothyroid patients: A randomized, double-blind, placebo-controlled trial. Complementary Ther. Med. 2020;48:102234. doi: 10.1016/j.ctim.2019.102234.Lowe J.R., Briggs A.M., Whittle S., Stephenson M.D. A systematic review of the effects of probiotic administration in inflammatory arthritis. Complement Ther. Clin. Pract. 2020;40:101207. doi: 10.1016/j.ctcp.2020.101207.Lowe J.R., Briggs A.M., Whittle S., Stephenson M.D. A systematic review of the effects of probiotic administration in inflammatory arthritis. Complement Ther. Clin. Pract. 2020;40:101207. doi: 10.1016/j.ctcp.2020.101207.Zamani B., Golkar H.R., Farshbaf S., Emadi-Baygi M., Tajabadi-Ebrahimi M., Jafari P., Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Int. J. Rheum. Dis. 2016;19:869–879. doi: 10.1111/1756-185X.12888.Zamani B., Golkar H.R., Farshbaf S., Emadi-Baygi M., Tajabadi-Ebrahimi M., Jafari P., Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Int. J. Rheum. Dis. 2016;19:869–879. doi: 10.1111/1756-185X.12888.Hao Y, Xu Y, Ban Y, Li J, Wu B, Ouyang Q, Sun Z, Zhang M, Cai Y, Wang M, Wang W. Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. Front Cell Infect Microbiol. 2022 Oct 6;12:983027. doi: 10.3389/fcimb.2022.983027.Hao Y, Xu Y, Ban Y, Li J, Wu B, Ouyang Q, Sun Z, Zhang M, Cai Y, Wang M, Wang W. Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. Front Cell Infect Microbiol. 2022 Oct 6;12:983027. doi: 10.3389/fcimb.2022.983027.Li JY, Yu M, Pal S, et al. Microbiota dependent production of butyrate is required for the bone anabolic activity of PTH. J Clin Invest. 2020.Li JY, Yu M, Pal S, et al. Microbiota dependent production of butyrate is required for the bone anabolic activity of PTH. J Clin Invest. 2020.Szczuko M., Zapalowska-Chwyć M., Drozd R. A Low Glycemic Index Decreases Inflammation by Increasing the Concentration of Uric Acid and the Activity of Glutathione Peroxidase (GPx3) in Patients with Polycystic Ovary Syndrome (PCOS) Molecules. 2019;24:1508. doi: 10.3390/molecules24081508.Szczuko M., Zapalowska-Chwyć M., Drozd R. A Low Glycemic Index Decreases Inflammation by Increasing the Concentration of Uric Acid and the Activity of Glutathione Peroxidase (GPx3) in Patients with Polycystic Ovary Syndrome (PCOS) Molecules. 2019;24:1508. doi: 10.3390/molecules24081508.Rebello CJ, O’Neil CE, Greenway FL. Dietary fiber and satiety: the effects of oats on satiety. Nutr Rev. 2016 Feb;74(2):131-47. doi: 10.1093/nutrit/nuv063.Rebello CJ, O’Neil CE, Greenway FL. Dietary fiber and satiety: the effects of oats on satiety. Nutr Rev. 2016 Feb;74(2):131-47. doi: 10.1093/nutrit/nuv063.Yoon SJ, Chu DC, Raj Juneja L. Chemical and physical properties, safety and application of partially hydrolized guar gum as dietary fiber. J Clin Biochem Nutr. 2008 Jan;42(1):1-7. doi: 10.3164/jcbn.2008001.Yoon SJ, Chu DC, Raj Juneja L. Chemical and physical properties, safety and application of partially hydrolized guar gum as dietary fiber. J Clin Biochem Nutr. 2008 Jan;42(1):1-7. doi: 10.3164/jcbn.2008001.Yasukawa Z, Inoue R, Ozeki M, Okubo T, Takagi T, Honda A, Naito Y. Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. Nutrients. 2019 Sep 10;11(9):2170. doi: 10.3390/nu11092170.Yasukawa Z, Inoue R, Ozeki M, Okubo T, Takagi T, Honda A, Naito Y. Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. Nutrients. 2019 Sep 10;11(9):2170. doi: 10.3390/nu11092170.Niv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T, Vaisman N. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016 Feb 6;13:10. doi: 10.1186/s12986-016-0070-5.Niv E, Halak A, Tiommny E, Yanai H, Strul H, Naftali T, Vaisman N. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016 Feb 6;13:10. doi: 10.1186/s12986-016-0070-5.

The authors declare that there are no conflicts of interest present.